Article · Revue · 2026

Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis

Basile Njei, Yazan Al-Ajlouni, Dam Nsoh Tanih, Ulrick Sidney Kanmounye, Sarpong Boateng, Khaled W. Halwani et 2 autres

Cost Effectiveness and Resource Allocation

• Accès ouvert · Doré
• Top 10 % mondial
• International · 3 pays

Le lire10.1186/s12962-026-00741-0